Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Director · Pres. Research & Development | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,729 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 2,531 · Balance 21,729 |
| Common StockSEC Table I · non-derivative | IndirectBy Young-Plaisance Revocable Trust | 1,242 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,242 |
| Common StockSEC Table I · non-derivative | IndirectBy Family Entities | 432 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 432 |
| Common StockSEC Table I · non-derivative | IndirectBy CorLyst, LLC | 1,009 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,009 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2021 Filed Oct 4, 2021 20:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017825 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Jan 6, 2022 20:57 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000708 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014741 · doc1.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,964 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013185 · doc1.xml · derivative · entry 3 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013185 · doc1.xml · derivative · entry 2 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858 Underlying: Common Stock · 12,858 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals. F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013185 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022. F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022. Read SEC document |
| June 23, 2021 Filed Jun 23, 2021 21:12 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 10,000 | $7.67 | $76,716.00 |
DisclosureSEC source: 0001567619-21-012540 · doc1.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,190 Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:04 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011978 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 8,127 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.